Skip to main content
. Author manuscript; available in PMC: 2013 Oct 28.
Published in final edited form as: AIDS. 2009 Sep 10;23(14):10.1097/QAD.0b013e32832ec1dc. doi: 10.1097/QAD.0b013e32832ec1dc

Fig. 2. Recovery of replication-competent HIV from the resting CD4+ T cells of aviremic patients treated with HDAC inhibitors: MRK 1 (class I HDACs 1, 2, and 3 and class II HDAC6), VPA (nonselective), or MRK 10 or 11 (class II HDACs).

Fig. 2

Patient cells were subjected to maximum mitogen stimulation or exposed to 2 µmol/l MRK 1, 40 µmol/l VPA, 2 µmol/l MRK 10 and 10 µmol/l MRK 11 for 24 h. Cells were washed and co-cultured with CD8-depleted PBMC as detailed in methods. Frequency of virus outgrowth from cells treated with HDACi was compared to the frequency of outgrowth from maximally stimulated cells (PHA). Each icon represents independent studies of patient cell samples; patient samples were simultaneously tested with mitogen or HDACi on the same day. Dashed lines indicate the limit of detection of the assay. HDAC, histone deacetylase; PBMC, peripheral blood mononuclear cell; VPA, valproic acid.